Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Cynosure Group LLC

Cynosure Group LLC decreased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,841 shares of the biopharmaceutical company's stock after selling 3,601 shares during the quarter. Cynosure Group LLC's holdings in Intra-Cellular Therapies were worth $905,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ITCI. Norges Bank bought a new stake in Intra-Cellular Therapies in the 4th quarter valued at about $268,347,000. Raymond James Financial Inc. bought a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at approximately $76,451,000. TimesSquare Capital Management LLC boosted its position in shares of Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company's stock worth $70,179,000 after buying an additional 402,186 shares during the period. Franklin Resources Inc. grew its holdings in Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock worth $129,463,000 after buying an additional 155,655 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company's stock valued at $811,928,000 after acquiring an additional 93,107 shares during the period. Institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI remained flat at $131.87 during mid-day trading on Friday. The stock's 50 day simple moving average is $129.62 and its 200 day simple moving average is $101.43. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.98.

Remove Ads

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. As a group, sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ITCI. Cantor Fitzgerald reiterated a "neutral" rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $140.00 to $132.00 in a research note on Monday, February 24th. StockNews.com began coverage on shares of Intra-Cellular Therapies in a research note on Saturday. They issued a "hold" rating for the company. Finally, Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has an average rating of "Hold" and an average price target of $106.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.